PMID- 24610289
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 2078-2101 (Print)
IS  - 2078-2101 (Linking)
VI  - 1
IP  - 15
DP  - 2014 Jan
TI  - Superior vena cava obstruction (SVCO) in patients with advanced non small cell 
      lung cancer (NSCLC).
PG  - 56-62
AB  - INTRODUCTION: To report on prognostic and treatment factors influencing the 
      response of SVCO and related survival outcomes in advanced non small cell lung 
      cancer. MATERIAL AND METHODS: From November 2008 through December 2011, 18 
      consecutively diagnosed NSCLC patients with SVCO were included in this study. The 
      patient, tumor and treatment related factors were analyzed. Median overall 
      survival (OS), Kaplan -Meier survival plots, T-test, Cox Proportional Hazards 
      models were generated by multiple covariates (MVA) and analyzed on SPSS software 
      (version 19.0; SPSS, Inc., Chicago, IL). RESULTS: Thirteen patients (72%) had 
      presented with SVCO before the pathological diagnosis of underlying lung 
      malignancy, while 5 (28%) progressed to SVCO after initiating treatment with 
      chemotherapy. Twelve (68%) patients achieved subjective relief from the 
      obstruction at the completion of palliative radiation therapy. Treating 
      oncologists preferred 4 Gy per fraction in 11 (62%), while the median 
      biologically equivalent dose delivered was 28 Gy. Six (33%) patients received 
      chemotherapy during the course of treatment. Median OS of the entire cohort was 
      3+/-1.85mths and 1-year survival rate of 7%. Univariate analysis confirmed that 
      SVCO patients with good performance score (p=0.02), and partial response to 
      chemotherapy (p= 0.001) have superior OS. However, Cox regression modeling for 
      MVA demonstrated only good performance SVCO patients (p = 0.05) have a better OS. 
      CONCLUSION: RT effectively relieves SVCO but overall poor survival associated in 
      our clinical scenario needs to be improved with multimodality approach. Adjuvant 
      chemotherapy is to be considered after initial radiation therapy in good 
      performance patients. KEYWORDS: superior vena cava obstruction (SVCO), radiation 
      therapy, chemotherapy, non small cell lung cancer (NSCLC), BED (biologically 
      equivalent dose).
FAU - Lee, H N
AU  - Lee HN
AD  - Lee Hsueh Ni, Assistant Professor, Radiation Oncology, STM Cancer Research 
      Institute, Himalayan Institute Hospital Trust, Swami Ram Nagar, Jolly Grant, 
      Dehradun, India 248140. Office Tel. +91 135 2471127. Fax +91 135 2471190. Email: 
      leehsueh@gmail.com.
FAU - Tiwana, M S
AU  - Tiwana MS
AD  - Surgical Oncology,STM Cancer Research Institute, Himalayan Institute Hospital 
      Trust, Swami Ram Nagar, Jolly Grant, Dehradun, India.
FAU - Saini, M
AU  - Saini M
AD  - Radiodiagnosis, STM Cancer Research Institute, Himalayan Institute Hospital 
      Trust, Swami Ram Nagar, Jolly Grant, Dehradun, India.
FAU - Verma, S K
AU  - Verma SK
AD  - Medical Oncology, STM Cancer Research Institute, Himalayan Institute Hospital 
      Trust, Swami Ram Nagar, Jolly Grant, Dehradun, India.
FAU - Saini, M
AU  - Saini M
AD  - Radiodiagnosis, STM Cancer Research Institute, Himalayan Institute Hospital 
      Trust, Swami Ram Nagar, Jolly Grant, Dehradun, India.
FAU - Jain, N
AU  - Jain N
AD  - Surgical Oncology, STM Cancer Research Institute, Himalayan Institute Hospital 
      Trust, Swami Ram Nagar, Jolly Grant, Dehradun, India.
FAU - Gupta, M
AU  - Gupta M
AD  - Surgical Oncology, STM Cancer Research Institute, Himalayan Institute Hospital 
      Trust, Swami Ram Nagar, Jolly Grant, Dehradun, India.
FAU - Chauhan, N
AU  - Chauhan N
AD  - Pathology, STM Cancer Research Institute, Himalayan Institute Hospital Trust, 
      Swami Ram Nagar, Jolly Grant, Dehradun, India.
LA  - eng
PT  - Journal Article
PL  - Kuwait
TA  - Gulf J Oncolog
JT  - The Gulf journal of oncology
JID - 101500911
SB  - IM
EDAT- 2014/03/13 06:00
MHDA- 2014/03/13 06:01
CRDT- 2014/03/11 06:00
PHST- 2013/11/14 00:00 [accepted]
PHST- 2014/03/11 06:00 [entrez]
PHST- 2014/03/13 06:00 [pubmed]
PHST- 2014/03/13 06:01 [medline]
PST - ppublish
SO  - Gulf J Oncolog. 2014 Jan;1(15):56-62.